RxDoctor Payments Data

Julie Aspiras, MD

Internal Medicine · Oceanside, CANPI 1952468183

Payments from drug & device makers

$2,103in general payments, 2019–2025

Across 93 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$585
  • Kowa Pharmaceuticals America, Inc.$289
  • AbbVie$259
  • Otsuka America Pharmaceutical, Inc.$186
  • Edwards Lifesciences$172
  • Merck$100
  • plus $514 from 12 others

What the payments were for

  • Food & beverage$2,103100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,103 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$316,133
Medicare patients
104
Services billed
4,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide28$47,273
EliquisApixaban35$44,601
OzempicSemaglutide26$38,580
Repatha SureclickEvolocumab16$26,393
JanuviaSitagliptin Phosphate20$24,662
JardianceEmpagliflozin12$20,417
ProliaDenosumab11$19,357
Levothyroxine Sodium191$2,170
Temazepam40$1,938
Celecoxib18$1,778
SynthroidLevothyroxine Sodium22$1,521
Nebivolol Hcl23$1,473
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$1,364
Memantine Hcl ErMemantine Hcl14$1,321
Albuterol Sulfate HfaAlbuterol Sulfate29$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$99$47,27328 claims
PfizerEliquis$88$44,60135 claims
MerckJanuvia$100$24,66220 claims
Boehringer IngelheimJardiance$73$20,41712 claims
AmgenProlia$585$19,35711 claims
AbbVieSynthroid$259$1,52122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oceanside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →